Durvalumab Benefit in Biliary Tract Cancer Not Diminished by Antibiotic Use
Durvalumab Benefit in Biliary Tract Cancer Not Diminished by Antibiotic Use is organized by Projects In Knowledge Inc. (PIK).
Release Date: Jan 25, 2023
Termination Date: Jan 24, 2024
Activity Goal:
The goal of this program is to provide data from medical meetings, expert analysis insights on current and emerging management strategies, and interactive case studies based on the most up-to-date evidence-based medicine and clinical trial results in HCC.
Learning Objective(s):
• Evaluate the latest clinical trial data regarding immune checkpoint inhibitors (ICIs), and emerging combinations for the treatment of advanced BTC and HCC.
• Create individualized treatment plans for advanced BTC by utilizing updated clinical guidelines to advance care.
Additional details will be posted as soon as information is available